Chimerix, Inc.
Index- P/E0.65 EPS (ttm)1.96 Insider Own0.80% Shs Outstand88.06M Perf Week-9.86%
Market Cap118.30M Forward P/E- EPS next Y-0.83 Insider Trans1.70% Shs Float79.26M Perf Month-21.47%
Income172.20M PEG- EPS next Q-0.25 Inst Own62.30% Short Float / Ratio3.53% / 3.72 Perf Quarter-35.35%
Sales33.80M P/S3.50 EPS this Y195.10% Inst Trans-1.65% Short Interest2.80M Perf Half Y-38.76%
Book/sh2.92 P/B0.44 EPS next Y-143.70% ROA99.50% Target Price7.33 Perf Year-75.05%
Cash/sh2.35 P/C0.54 EPS next 5Y- ROE113.50% 52W Range1.27 - 5.39 Perf YTD-31.18%
Dividend- P/FCF- EPS past 5Y26.80% ROI-23.50% 52W High-76.25% Beta1.21
Dividend %- Quick Ratio11.20 Sales past 5Y49.70% Gross Margin98.70% 52W Low0.79% ATR0.08
Employees89 Current Ratio11.20 Sales Q/Q30325.20% Oper. Margin- RSI (14)25.35 Volatility4.12% 5.24%
OptionableYes Debt/Eq0.00 EPS Q/Q47.60% Profit Margin- Rel Volume0.86 Prev Close1.28
ShortableYes LT Debt/Eq0.00 EarningsMar 02 BMO Payout0.00% Avg Volume753.37K Price1.28
Recom1.70 SMA20-15.26% SMA50-24.71% SMA200-34.76% Volume651,264 Change0.00%
Sep-07-22Initiated CapitalOne Overweight $7
Apr-29-21Initiated Maxim Group Buy $20
Apr-23-21Resumed Cowen Outperform $10 → $18
Mar-31-21Initiated Wedbush Outperform $21
Mar-31-21Initiated Jefferies Buy $21
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Feb-23-16Downgrade Morgan Stanley Equal-Weight → Underweight
Show Previous Ratings
Mar-06-23 05:51AM
Mar-03-23 06:57PM
Mar-02-23 10:10PM
Feb-28-23 04:05PM
07:00AM Loading…
Feb-23-23 07:00AM
Feb-17-23 09:04AM
Feb-13-23 05:55PM
Feb-07-23 01:51PM
Feb-02-23 02:19PM
Jan-19-23 10:49AM
Jan-05-23 07:00AM
Dec-27-22 02:53PM
Dec-12-22 01:41PM
Dec-08-22 05:00PM
12:00PM Loading…
Nov-29-22 12:00PM
Nov-10-22 04:30PM
Nov-07-22 06:06AM
Nov-04-22 12:27PM
Nov-03-22 08:15AM
Nov-01-22 10:01AM
Oct-27-22 04:30PM
Oct-26-22 11:52AM
Sep-27-22 09:59PM
04:05PM Loading…
Sep-26-22 04:05PM
Sep-10-22 09:16AM
Sep-06-22 07:00AM
Sep-01-22 08:48AM
Aug-30-22 02:17PM
Aug-29-22 10:45AM
Aug-17-22 09:29AM
Aug-09-22 04:00AM
Aug-08-22 04:01PM
Aug-02-22 07:00AM
Aug-01-22 04:01PM
Jul-25-22 04:30PM
Jul-16-22 09:45AM
Jun-24-22 03:08PM
Jun-23-22 09:15AM
Jun-22-22 07:00AM
Jun-16-22 09:10AM
Jun-09-22 06:28AM
Jun-01-22 04:30PM
May-24-22 08:04AM
May-23-22 11:39AM
May-20-22 08:38AM
May-18-22 11:41AM
May-17-22 04:15PM
May-16-22 04:46PM
May-12-22 04:15PM
May-09-22 07:00AM
Apr-04-22 08:53AM
Apr-03-22 01:51PM
Mar-21-22 07:00AM
Mar-01-22 06:30PM
Feb-28-22 07:00AM
Feb-24-22 05:50PM
Feb-22-22 07:00AM
Feb-17-22 03:03PM
Feb-03-22 08:23AM
Feb-02-22 05:41AM
Jan-20-22 08:00AM
Jan-18-22 04:01PM
Jan-12-22 12:52PM
Jan-03-22 04:45PM
Dec-28-21 05:34AM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-14-21 09:01AM
Dec-10-21 09:38PM
Nov-22-21 04:21AM
Nov-19-21 07:00AM
Nov-12-21 08:00AM
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jakeman DavidPrincipal Accounting OfficerJan 26Sale1.763,2305,686136,752Jan 26 05:23 PM
MIDDLETON FRED ADirectorSep 29Buy1.8620,00037,17640,000Oct 03 12:21 PM
Jakeman DavidPrincipal Accounting OfficerSep 29Sale1.864,4008,185127,532Sep 30 10:22 AM
Andriole Michael T.Chief Business Officer and CFOAug 25Option Exercise2.0950,000104,500262,724Aug 29 05:03 PM
Sherman Michael A.Chief Executive OfficerJul 25Option Exercise2.09100,000209,000125,364Jul 26 09:25 PM
MIDDLETON FRED ADirectorMay 19Buy2.0420,00040,73820,000May 20 03:29 PM
Meyer Robert J.DirectorMay 19Buy2.0611,40023,47026,400May 20 10:35 AM
Andriole Michael T.Chief Business Officer and CFOMay 17Buy1.7115,00025,635212,724May 18 11:04 AM
DEMSKI MARTHA JDirectorMay 17Buy1.6110,00016,10054,055May 17 05:39 PM